Replies to post #122404 on Biotech Values

[genisi]

Forgot Prana's compound which also showed reduction of CSF Abeta.

[mcbio]

Different approaches but all aiming Abeta: Cytos (partner with NVS) has a peptide vaccine in phase II, Transition Therapeutics (partner with Elan) with a scyllo-inositol, NeuroGenetic, EnVivo, and Satori are all in the gamma secretase modulators area and CoMentis (partner with Astellas) has a BACE inhibitor.

Thanks genisi. LGND also has royalty rights to a BACE inhibitor being developed by MRK in Phase 1 I believe.

Any of these that you view as more promising? The Phase 2 results for TTHI's ELND005 didn't exactly strike me as too promising.

[DewDiligence]

Astellas dumps CoMentis BACE-for-AD collaboration:

http://www.astellas.com/en/corporate/news/detail/astellas-and-comentis-to-end-a.html